Treated With Angiotensin-Converting Enzyme Inhibition Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients

[PDF] [Full Text] [Abstract] , October 1, 2002; 303 (1): 232-237. J Pharmacol Exp Ther Agostoni and Albert Adam Giuseppe Molinaro, Massimo Cugno, Mélissa Perez, Yves Lepage, Nicole Gervais, Angelo -Bradykinin 9 Slower Degradation of des-Arginine Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a [PDF] [Full Text] [Abstract] , December 1, 2004; 44 (6): 913-918. Hypertension Newby Nicholas L.M. Cruden, Keith A.A. Fox, Christopher A. Ludlam, Neil R. Johnston and David E. Treated With Angiotensin-Converting Enzyme Inhibition Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients [PDF] [Full Text] [Abstract] , August 31, 2005; 25 (35): 7986-7992. J. Neurosci. Allchorne, Ru-Rong Ji and Clifford J. Woolf Haibin Wang, Tatsuro Kohno, Fumimasa Amaya, Gary J. Brenner, Nobuko Ito, Andrew Synaptic Transmission Bradykinin Produces Pain Hypersensitivity by Potentiating Spinal Cord Glutamatergic [PDF] [Full Text] [Abstract] , January 1, 2008; 51 (1): 141-147. Hypertension Adam and Nancy J. Brown James Brian Byrd, Karine Touzin, Saba Sile, James V. Gainer, Chang Yu, John Nadeau, Albert Angioedema Associated − Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor [PDF] [Abstract] , December , 2008; 9 (4): 221-225. Journal of Renin-Angiotensin-Aldosterone System Amy L Cilia La Corte, Angela M Carter, Anthony J Turner, Peter J Grant and Nigel M Hooper contraceptive pill The bradykinin-degrading aminopeptidase P is increased in women taking the oral

[1]  J. Rouleau,et al.  The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins , 2000, Peptides.

[2]  A. Adam,et al.  Anomaly of the des‐Arg9‐bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: a preliminary study , 1999, Transfusion.

[3]  T. Kanda,et al.  Hormone replacement therapy in postmenopausal women with essential hypertension increases circulating plasma levels of bradykinin. , 1999 .

[4]  J. Rouleau,et al.  Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. , 1999, Immunopharmacology.

[5]  P. Thibault,et al.  Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P , 1999, Peptides.

[6]  M. Thomas,et al.  Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. , 1999, Kidney international.

[7]  M. Chappell,et al.  Estrogen regulation of angiotensin-converting enzyme mRNA. , 1999, Hypertension.

[8]  D. Bachvarov,et al.  The B1 receptors for kinins. , 1998, Pharmacological reviews.

[9]  N. Denslow,et al.  Assignment of the membrane-bound human aminopeptidase P gene (XPNPEP2) to chromosome Xq25. , 1998, Genomics.

[10]  A. Schmaier,et al.  Plasma contact activation: a revised hypothesis. , 1998, Biological Research.

[11]  R. Skidgel,et al.  Metabolism of Bradykinin by Peptidases in Health and Disease , 1997, The Kinin System.

[12]  A. Schmaier,et al.  Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. , 1997, Blood.

[13]  A. Adam,et al.  Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. , 1997, American journal of physiology. Heart and circulatory physiology.

[14]  H. Ju,et al.  Cloning and tissue distribution of human membrane-bound aminopeptidase P. , 1997, Biochimica et biophysica acta.

[15]  R. Colman,et al.  Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat , 1997 .

[16]  R. Colman,et al.  Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. , 1997, Arthritis and rheumatism.

[17]  A. Adam,et al.  Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. , 1996, The American journal of physiology.

[18]  N. Key,et al.  Hypotensive reactions to white cell‐reduced plasma in a patient undergoing angiotensin‐converting enzyme inhibitor therapy , 1996, Transfusion.

[19]  E. Jaspard,et al.  Catalytic properties of the two active sites of angiotensin I-converting enzyme on the cell surface. , 1995, Biochemical and biophysical research communications.

[20]  F. Marceau.  Kinin B1 receptors: a review. , 1995, Immunopharmacology.

[21]  T. Unger,et al.  Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. , 1995, Pharmacological reviews.

[22]  F. Marceau,et al.  Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. , 1995, Journal of immunological methods.

[23]  R. Skidgel.  Human carboxypeptidase N: lysine carboxypeptidase. , 1995, Methods in enzymology.

[24]  A. Adam,et al.  Development of digoxigenin-labeled peptide: Application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues , 1994, Peptides.

[25]  T. Unger,et al.  Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. , 1994, Cardiovascular research.

[26]  R. Colman,et al.  Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. , 1993, Blood.

[27]  Lei Wei,et al.  Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. , 1993, The Journal of biological chemistry.

[28]  J. Neter,et al.  Applied Linear Statistical Models (3rd ed.). , 1992 .

[29]  W. Hall,et al.  Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy , 1992, Annals of Internal Medicine.

[30]  W. Simmons,et al.  Membrane-bound aminopeptidase P from bovine lung. Its purification, properties, and degradation of bradykinin. , 1992, The Journal of biological chemistry.

[31]  K. Bhoola,et al.  Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.

[32]  Y. Vanrenterghem,et al.  Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis , 1990, The Lancet.

[33]  J. Rice.  Mathematical Statistics and Data Analysis , 1988 .

[34]  F. Martínez-Brotons,et al.  Plasma Kallikrein-Kinin System in Patients with Uncomplicated Sepsis and Septic Shock-Comparison with Cardiogenic Shock , 1987, Thrombosis and Haemostasis.

[35]  P. Franchimont,et al.  Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. , 1985, Clinical chemistry.

[36]  A. Adam,et al.  Optimized Determination of Plasma Prokallikrein on a Hitachi 705 Analyser , 1985, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[37]  J. Riordan,et al.  Substrate specificity and kinetic characteristics of angiotensin converting enzyme. , 1983, Biochemistry.

[38]  P. Sestini,et al.  Kinetics and mechanisms. , 1982 .

[39]  R. Colman,et al.  The kinetics of the release of bradykinin by kallikrein in normal human plasma. , 1972, The Journal of laboratory and clinical medicine.

[40]  A. Freedman.  Handbook of Experimental Pharmacology, vol 14. , 1972 .

[41]  J. D. Fast,et al.  Kinetics and mechanisms , 1971 .